RU2432943C1 - Medication for treating mastitis in cows in lactation period - Google Patents

Abstract

FIELD: medicine. ^ SUBSTANCE: invention relates to field of veterinary. Medication contains, 5: cefotaxime sodium salt - 5.0-9.0, neomycin sulfate - 0.8-1.2, prednisolone - 0.1-0.3, emulsifier Riken DMG - 3, monoglyceride distilled - 1, vaseline oil - to 100. ^ EFFECT: medication makes it possible to increase efficiency of treating mastitis in lactating cows and reduce terms of milk sorting out. ^ 9 tbl, 5 ex

Description

The invention relates to the field of veterinary medicine.

Mastitis is an inflammation of the mammary gland that occurs in response to the effects of adverse mechanical, physical, chemical and biological factors.

The main factors contributing to the emergence and development of mastitis are the technical imperfection of milking machines, violation of the technology and rules of machine milking of cows. Initially, irritation occurs, which, when repeated, passes into aseptic inflammation - latent mastitis. The general and local resistance decreases, conditions are created for the penetration and reproduction of various opportunistic and pathogenic microflora, which causes inflammation of various forms from subclinical, proceeding on its own during one or two lactations and leading to atrophy, to clinically severe serous or catarrhal mastitis.

Breast diseases are widespread and cause great economic damage to livestock farming, amounting to hundreds of millions of rubles. It consists of the lack of milk, premature culling of cows, the high incidence of young animals, the cost of treatment. All this reduces the production and economic efficiency of dairy cattle breeding. Therefore, the development of new effective means, methods of treatment and prevention of mastitis in cows is of current importance.

Currently, various drugs are produced for the treatment of mastitis cows, including, as a rule, antimicrobial substances - antibiotics, sulfonamide, nitrofuran and other drugs. But not all of them give the desired effect, which, first of all, is explained by a decrease in the sensitivity to these substances of microflora, which causes mastitis. In this regard, there is a need to create new highly effective antimicrobial drugs with a wide spectrum of action with a minimum milk rejection period.

As an analogue to the proposed drug, we took the drug Cobactan LC, intended for the treatment of mastitis in lactating cows, containing cefkin and an oil base in the following ratio of components:

Cefkinoma sulfate - 75.0 mg

Oil base up to 8 ml

The dose of administration is 8 ml in the nipple cistern of the udder with an interval of 12 hours until complete recovery [Instructions for use of Cobactan LC. Registration number PVI-2-4.7 / 02201].

The disadvantage of this drug is that it contains only one antibacterial agent - cefkinoma sulfate. In this regard, this drug cannot provide a high therapeutic effect in the treatment of mastitis, since with prolonged use, it quickly forms resistance in microorganisms - causative agents of mastitis.

The prototype of the invention is a drug for the treatment of mastitis in cows during lactation mastilex, which contains two antimicrobial agents - cephalexin monohydrate from the group of cephalosporins and gentamicin sulfate from the group of aminoglycosides. The drug is administered intracisternally in an amount of 10 ml with an interval of 12-24 hours until complete recovery, with the following ratio of components:

Cephalexin Monohydrate - 350 mg

Gentamicin sulfate - 35 mg.

Milk-dispersed filler up to 10 ml.

[Veterinary preparations of Russia. Directory. M., 2004. Part 1. - S. 467].

The disadvantage of this drug is a decrease in its therapeutic efficacy with prolonged use, associated with the development of the resistance of microorganisms to the active component of the drug cephalexin monohydrate, due to the fact that it, being first-generation cephalosporin, has a low antimicrobial effect against the main causative agents of mastitis. For example, it manifests its effect against staphylococcus aureus in a concentration of up to 12.5 μg / ml or more; Streptococcus feces - more than 50 mcg / ml; E. coli up to 25 μg / ml or more [S.M.Navashin, I.P. Fomina. Rational antibiotic therapy. Directory. M., "Medicine" 1982, pp. 132-133]. In addition, the active substances of this drug are excreted from the mammary gland only on the fifth day after the last injection of the drug, which leads to the rejection of large quantities of milk.

The technical result of the invention is to increase therapeutic efficacy and reduce the time for rejection of milk.

The technical result is achieved through the use of chemotherapeutic agents of cefotaxime sodium salt, neomycin sulfate, as effective broad-spectrum antibiotics, with insufficient activity of other antibiotics, and prednisone, which has a strong anti-inflammatory effect in the form of a stable suspension in an oil base.

Compared with the prototype preparation, the essential distinguishing features of the present invention are those that characterize the introduction of broad-spectrum antibiotics to the preparation of cefotaxime sodium salt, neomycin sulfate, prednisolone and a base that reduces the elimination period of active drug components from the mammary gland to 3 days.

The drug for the treatment of mastitis in cows during lactation consists of the following components:

Cefotaxime sodium salt - 5.0-9.0%

Neomycin sulfate - 0.8-1.2%

Prednisolone - 0.1-0.3%

Emulsifier Riken DMG - 3%

Distilled monoglyceride - 1%

Vaseline oil up to 100%

The achievement of the technical result from the use of the proposed preparation is explained by the fact that cefotaxime sodium salt, which is part of the preparation, is a third generation cephalosporin antibiotic, acting bactericidal, has a wide spectrum of antimicrobial activity, is active against gram-positive and gram-negative microorganisms that are resistant to other antibiotics: Staphylococcus spp. (including Staphylococcus aureus, including penicillin-forming strains), Staphylococcus epidermidis, Streptococcuspyogenes, Streptococcus agalactiae, Enterobacter spp Escherichia coli Citrobacter spp. Resistant to most beta-lactamases of gram-positive and gram-negative microorganisms, staphylococcus penicillinase [Instructions for use of the drug cefotaxime sodium salt registration number P No. 002159 / 01-2003, 2006].

Cefotaxime sodium salt acts bactericidal, which is associated with its inhibitory effect on cell wall formation; similarly to penicillin, it inhibits the activity of the transpeptidase enzyme involved in the biosynthesis of bacterial cell walls. [D.A. Kharkevich. Pharmacology. - M .: GEOTAR Medicine, 2000, S.508].

Neomycin sulfate, a broad-spectrum antibiotic, is active against most gram-negative and gram-positive microorganisms. Pathogenic staphylococci, corynebacteria, E. coli are sensitive to its action. Neomycin sulfate has a bactericidal effect on microorganisms that are at various stages of development, including at rest [S.M. Navashin, I.P. Fomina. Rational antibiotic therapy. Directory. M., "Medicine", 1982, S.233-236].

Prednisolone has an anti-inflammatory effect, reduces inflammation and swelling of the tissues of the udder. The anti-inflammatory effect is mainly due to stabilization of cell membranes (including mast and lysosomes), inhibition of phospholipase A ₂ and hyaluronidase activity, release of arachidonic acid from phospholipids of cell membranes (with a decrease in the level of its metabolic products - prostaglandins, thromboxane and leukotrienes), as well as inhibition mast cell division and their degranulation (histamine, serotonin and bradykinin release), synthesis of platelet activation factor and connective tissue proliferation [M.D. Mashkovsky. Medicines - M.: RIA "New Wave": Publisher Umerenkov, 2008, P.565].

The distilled monoglyceride and emulsifier Riken DMG introduced into the preparation are used as emulsifiers and stabilizers of edible fats, cosmetic creams, pharmaceutical ointments, plasticizers [Chemical Encyclopedia. M .: Publishing. “Owls. Encyclopedia ”, 1989, vol. 1, p. 584-585].

The drug for the treatment of mastitis in cows during lactation is used during lactation to treat all forms of mastitis. Before the introduction of the drug, the secretion of the udder is extruded from the affected lobe and disposed of, the nipple is disinfected. Before use, the contents of the syringe of the tube or vial are heated to 37 ° C, shaken thoroughly until a uniform suspension is obtained, 5 ml are taken from the vial into a sterile syringe. The syringe or syringe tube is tightly pressed to the outer opening of the nipple canal, the drug is injected into the nipple cistern by carefully pressing the syringe plunger. After the introduction, a light massage of the nipple of the affected lobe of the udder is conducted from the bottom up. Depending on the severity of the inflammatory process, the drug is administered in a dose of 5 ml once a day (preferably after evening milking) with an interval of 24 hours until the affected portion of the udder is completely cured (2-4 injections).

During treatment and within 3 days after the last administration of the drug, milk from the affected udder lobes is dispensed into a separate bowl, neutralized and disposed of, and the animals are fed from the remaining udder lobes after boiling.

The drug for the treatment of mastitis in cows during lactation is made as follows. To obtain a dispersed medium, 3% Riken DMG emulsifier and 1% distilled monoglyceride are melted in liquid paraffin, added to 100% at a temperature of 70 ° C. The mixture is autoclaved at a temperature of 120 ° C for 1.5-2 hours, then cooled to 30-35 ° C. Powder of cefotaxime sodium salt 5-9%, neomycin sulfate 0.8-1.2% and prednisolone 0.1-0.3%, preliminarily ground in a ball mill, is added to a cooled base, the mixer is stirred for 15-20 minutes and packaged .

In appearance, the drug for the treatment of mastitis in cows during lactation is a stable, oily suspension of a viscous consistency with a specific odor, white in color with a cream tint. At a temperature of 37 ° C, the suspension has a liquid consistency. The drug completely retains its original properties (appearance, color, authenticity, mass fraction of cefotaxime sodium salt, neomycin sulfate and prednisolone, microbial purity, mechanical inclusions) and does not delaminate for 12 months of storage at temperatures from 0 to 25 ° С.

The use of milk for human consumption is allowed 72 hours after the last injection of the drug with the complete disappearance of the clinical signs of mastitis. Slaughter of animals for meat is allowed no earlier than 7 days after the administration of the drug. Meat of animals forced to be killed earlier than this period can be used for the production of meat and bone meal or for feed to fur animals.

The effectiveness of the drug for treating mastitis in cows during lactation was tested on cows belonging to the Sergievsky Breeding Plant OJSC of the Livensky District of the Oryol Region, Manino CJSC, the Kalacheevsky District of the Voronezh Region, and the Vyaznovatovka Joint Venture LLC of the Nizhnedevitsky District of the Voronezh Region.

The essence of the technical solution is illustrated by examples.

Example 1

To identify the optimal ratio of components and the effectiveness of the drug, three formulations were compiled:

Recipe No. 1: cefotaxime sodium salt - 5.0%; neomycin sulfate - 0.8%, prednisone - 0.1%; Riken DMG emulsifier - 3.0%; distilled monoglyceride - 1.0%; Vaseline oil up to 100%.

Recipe No. 2: cefotaxime sodium salt - 7.0%; neomycin sulfate - 1.0%; prednisone - 0.2%; Riken DMG emulsifier - 3.0%; distilled monoglyceride - 1.0%; Vaseline oil up to 100%.

Recipe No. 3: cefotaxime sodium salt - 9.0%; neomycin sulfate - 1.2%; prednisone - 0.3%; Riken DMG emulsifier - 3.0%; distilled monoglyceride - 1.0%; Vaseline oil up to 100%.

For the tests, 247 cows with various forms of mastitis were selected. All cows, according to the analogy principle, were divided into three groups, in the first group the cows had subclinical mastitis (n = 83), in the second - catarrhal (n = 84), in the third - purulent-catarrhal (n = 80). Cows were treated with the proposed drug with the appropriate formulation, in a dose of 5.0 ml once a day for 2-4 days. As a comparison drug was mastilex, which was used according to the instructions for its use. 5-7 days after the last injection of the preparations, the animals were examined clinically, and milk with a 2% solution of masttest, a breakdown of sedimentation and selectively by counting the content of somatic cells.

As can be seen from the data presented in tables 1-3, the proposed drug (formulation 1, 2, 3) against the reference drug mastilex has the highest therapeutic effect. Of the presented formulations of the drug for treating mastitis in cows during lactation, formulation No. 2 has the highest therapeutic effect, its effectiveness with subclinical mastitis was 95.0%, with catarrhal - 91.3%, and purulent-catarrhal - 90.9%, which by 8.1; 7.1; 13.1% higher than with mastilex treatment.

Thus, the proposed preparation with formulation No. 2: cefotaxime sodium salt - 7.0%, neomycin sulfate - 1.0%, prednisolone - 0.2%, emulsifier Riken DMG - 3%, distilled monoglyceride - 1%, liquid paraffin 100%, has a high therapeutic effect in comparison with the prototype drug mastilex.

Example 2

Antimicrobial activity of the drug ((formulation No. 2) cefotaxime sodium salt - 7.0%, neomycin sulfate - 1.0%, prednisolone - 0.2%, emulsifier Riken DMG - 3%, distilled monoglyceride - 1%, liquid paraffin up to 100 %) for the treatment of mastitis in cows during lactation and its components was studied by the method of serial dilutions in a liquid nutrient medium, followed by seeding on solid nutrient media.

For the experiment, we used strains of pathogenic microorganisms isolated from the secretion of the mammary gland of patients with mastitis of cows and museum strains.

The results of the experiment are presented in table 4.

Table 4 Antimicrobial activity of cefotaxime, neomycin and their combination against the main causative agents of mastitis No. p / p Microorganism cultures Concentration, mcg / ml cefotaxime neomycin cefotaxime: neomycin 7: 1 MBSK MBCC MBSK MBCC MBSK MBCC one. Staphilococcus aureus 209 P 0.78 1,56 3.12 6.25 0.39 0.78 2. Streptoccocus gr. AT 1,56 12.5 6.25 12.5 0.39 0.78 3. E.coli 0139 1,56 12.5 25.0 50,0 0.78 1,56 four. E.coli 0149 6.25 12.5 3.12 6.25 0.39 0.78 5. E.coli 0137 0.78 1,56 0.78 3.12 0.39 0.78 6. Enterococcus faecalis 6.25 25 6.25 25 0.78 1,56 7. Ps. aeruginosa 12.5 50,0 3.12 25.0 1,56 6.25 8. Average value 6.8 20.6 6.1 16.8 1,02 3.22

As can be seen from the data presented (Table 4), the combination of cefotaxime sodium salt and neomycin sulfate in the ratio of 7: 1 has a wide spectrum and high antimicrobial activity against the main causative agents of mastitis at a concentration of 0.78-6.25 μg / ml, which exceeds the antimicrobial activity of cefotaxime and neomycin separately is 2-16 times.

The validity of this combination is due to the fact that two antibacterial components that have a bactericidal effect, but with a different mechanism, are simultaneously combined in the dosage form. The mechanism of action of cefotaxime sodium salt is associated with damage to the bacterial cell membrane (suppression of the synthesis of the peptidoglycan layer), which are in the process of reproduction, and the release of autolytic enzymes, which leads to their death. And at the same time, damaging the bacterial cell membrane, cefotaxime sodium salt promotes penetration of the neomycin sulophate into the microbial cell, which, in turn, disrupts protein synthesis in the microbial cell by irreversibly binding to one of the ribosome subunits and disrupting the synthesis of cytoplasmic membranes, which also leads to the death of bacterial cells. All this provides a synergistic effect of this composition.

Example 3

The effect of the drug for the treatment of mastitis in cows during lactation (recipe No. 2) on the mammary gland and the body of cows.

Study of the effect of the drug (cefotaxime sodium salt - 7.0%, neomycin sulfate - 1.0%, prednisolone - 0.2%, emulsifier Riken DMG - 3%, monoglyceride - 1%, petrolatum oil up to 100%) for the treatment of mastitis in cows during lactation on the mammary gland and the body of the animal was carried out in "OJSC Voronezhpishcheproduct" Novo-Usmansky district of the Voronezh region. For this, 3 clinically healthy cows were selected at 3-4 months of lactation. Previously, a clinical examination of the animals was carried out (measuring temperature, pulse, respiration, scar reduction, examination and palpation of the mammary gland), the study of milk with 2% Mastest solution, somatic cell count on a somatic cell counter “De Laval”. The drug, heated to 38 ° C, was introduced to the cows in the left front lobe of the udder, at a dose of 5 ml, after preliminary milk was milked and the nipples were treated with 70% ethanol, the right front lobe served as a control. After administration of the drug after 24, 48, 72, 96 hours, the state of the animals was determined, as well as the experimental and control shares of the udder. The number of somatic cells was determined using a De Laval somatic cell counter after visual inspection and examination of milk with a 2% masttest solution on a PMK-2 milk control plate.

The research results are shown in tables 5, 6 and 7.

It was found that after the intracisternal administration of the drug for the treatment of mastitis in cows during lactation (formulation No. 2), the reaction of the secretion of the udder from the experimental lobes after 24-72 hours was doubtful (+) and weakly positive (++), and then became negative, and in control shares the reaction was negative.

Table 5 The reaction with a 2% solution of masttest after intracisternal administration of the drug for the treatment of mastitis in cows during lactation Terms of study
niya, hour No. 1 Number 2 Number 3 Experience (l / p) Control (p / p) Experience (l / p) Control (p / p) Experience (l / p) Control (s / n) Before introduction - - - - - - In: 24 ++ - + - + - 48 + - + - + - 72 - - - - - -

When determining the number of somatic cells in the milk of experimental and control shares (Table 6), a slight increase was revealed 3-24 hours after the administration of the drug, and then a decrease after 48-72 hours, to the original number.

Table 6 The number of somatic cells thousand / ml after intracisternal administration of the drug for the treatment of mastitis in cows during lactation Terms of research
vania hour No. 1 Number 2 Number 3 average experience the control experience the control experience the control experience the control before introduction 345 340 276 265 453 287 358.0 ± 51.5 297.3 ± 22.3 in: 3 455 343 456 324 519 248 476.7 ± 21.2 305.0 ± 29.02 6 876 356 945 365 798 268 873.0 ± 42.5 329.7 ± 30.9 12 1323 316 1034 318 1045 353 1152.3 ± 86.3 395.7 ± 21.3 24 1438 323 1089 287 1165 286 1230.7 ± 105.1 298.7 ± 12.2 48 754 367 711 253 776 275 747.0 ± 19.1 298.3 ± 34.9 72 337 358 354 255 478 367 389.7 ± 44.4 326.7 ± 35.9

The change in the general condition of the animals was determined by indicators of behavior, appetite, temperature, pulse, respiration, and scar reduction. During the experiment, there were no changes in the state of the body of the experimental animals; indicators of temperature, pulse, respiration were normal (Table 7).

Table 7 The effect of the drug for the treatment of mastitis in cows during lactation on indicators of the general condition of the body of cows Study time, hour Indicators T ° C Pulse The number of breathing. movements in 1 min Quantity abbr. scar in 5 minutes Before introduction 38.2 ± 0.05 70.0 ± 1.51 17.0 ± 0.34 5.4 ± 0.13 in: 3 38.1 ± 0.07 71.0 ± 0.54 17.0 ± 0.34 5.4 ± 0.13 6 38.4 ± 0.05 71.6 ± 1.24 17.5 ± 0.17 5.4 ± 0.13 12 38.3 ± 0.08 72.6 ± 0.81 17.7 ± 0.65 6.3 ± 0.18 24 38.1 ± 0.03 73.3 ± 0.32 18.3 ± 0.54 6.5 ± 0.14 48 38.2 ± 0.05 73.0 ± 0.54 18.1 ± 0.15 5.3 ± 0.15 72 38.2 ± 0.08 71.6 ± 0.63 17.7 ± 0.34 5.3 ± 0.17

Thus, the drug for the treatment of mastitis in cows during lactation has a slight irritating effect on the mammary gland with intracisternal administration, which is expressed in the appearance of a dubious (+) and weakly positive (++) reaction of milk with a 2% masttest solution and an increase in the content of somatic cells in after 12 hours, the secretion of the udder is 3.2 times (from 358.0 ± 51.5 to 1134.0 ± 94.5 thousand / ml), after 24 hours, 3.4 times (1230.7 ± 106.0 thousand ./ml), further decreased, and after 72 hours their content (389.7 ± 44.4 thousand / ml) did not significantly differ from the initial level. From this it follows that the new drug, with a slight irritating effect on the mammary gland, is suitable for intracisternal administration in order to treat mastitis in cows during lactation.

Example 4

To conduct production tests of the drug for the treatment of mastitis in cows during lactation, two groups of animals were selected, 90 cows each. Each group was divided into three subgroups. Cows of the first group of the first subgroup were sick with subclinical mastitis (n = 32), the second subgroup of catarrhal mastitis (n = 30), the third subgroup of purulent-catarrhal (n = 28). Cows of the second group of the first subgroup were sick with subclinical mastitis (n = 31), the second subgroup of catarrhal (n = 30), the third subgroup of purulent-catarrhal (n = 29).

The animals of the first group were treated with a drug for the treatment of mastitis in cows during lactation (formulation No. 2) at a dose of 5.0 ml once a day for 2-4 days, animals of the second group were treated with mastilex according to the instructions for use. The drugs were administered after milking and nipple treatment with 70% ethyl alcohol. One day after each administration, all cows were subjected to clinical examination and milk testing from each cow with a 2% mastest solution before the end of treatment and within 5-7 days after treatment. The test results were taken into account by the percentage of cows recovered and remaining sick.

The test results are presented in table 8.

Table 8 The effectiveness of treatment of cows with various forms of mastitis Preparations Treated Multiplicity of drug administration Total recovered Cured cows share cows % share % Subclinical mastitis mastilex 31 39 2.85 ± 0.04 29th 93.5 36 92.3 drug for the treatment of mastitis in cows during lactation 32 40 2.67 ± 0.05 31 96.9 38 95.0 Catarrhal mastitis mastilex thirty 37 3.86 ± 0.12 25 83.3 32 86.5 drug for the treatment of mastitis in cows during lactation thirty 38 3.70 ± 0.06 27 90.0 34 89.5 Purulent catarrhal mastilex 29th 34 4.36 ± 0.11 24 82.7 27 79.4 drug for the treatment of mastitis in cows during lactation 28 33 4.15 ± 0.05 24 85.7 28 84.8

In the production environment it is shown (table 8) that the proposed drug, in the aggregate cefotaxime sodium salt, neomycin sulfate and prednisolone, provides a new ultraluminal effect in comparison with one of the analogues (mastilex).

Example 5

To determine the timing of the removal of the active components of the drug for the treatment of mastitis in cows during lactation from milk, urine, blood, 4 cows were selected for 4-5 months of lactation. The drug was injected into the affected lobes of 3 cows with catarrhal mastitis once a day four times in a dose of 5 ml, one cow served as a control, the drug was not administered to it.

After 1, 2, 3, 4 days after the end of treatment, samples of milk, blood, urine were taken to determine the residual amounts of cefotaxime sodium salt and neomycin sulfate.

It was established (Table 9) that, after a four-fold intracisternal administration of the drug for the treatment of mastitis in cows during lactation, its components cefotoxime sodium salt and neomycin sulfate are determined in milk for 3 days. Only neomycin sulfate is detected in the blood for 2 days.

Table 9 The residual amount of the drug for the treatment of mastitis in cows during lactation Object of study Study time after application 24 h 48 h 72 h 96 h Cefotoxime sodium salt Milk 5.42 4,5 1.25 0.00 3.42 3,1 0.75 0.00 3.70 3,5 0.64 0.00 Average 4.18 ± 0.61 3.7 ± 0.43 0.88 ± 0.19 0.00 Blood 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Average 0.00 0.00 0.00 0.00 Neomycin sulfate Milk 5,0 2.95 0.15 0.00 4.3 1.72 0.12 0.00 4.9 1.75 0.15 0.00 Average 4.7 ± 0.22 2.14 ± 0.38 0.14 ± 0.009 0.00 Blood 0.00 2.0 0.00 0.00 0.00 2,35 0.00 0.00 0.00 1.7 0.00 0.00 Average 0.00 2.02 ± 0.09 0.00 0.00

Thus, milk can be used in food 72 hours after the last injection of the drug for the treatment of mastitis in cows during lactation.

The drug for treating mastitis in cows during lactation has a higher therapeutic efficacy compared to the prototype drug, due to the use of cefotoxime sodium salt as an antibiotic with a wide spectrum of antibacterial action, neomycin sulfate is most effective for pathologies caused by Escherichia, staphylococci, protozoa, etc. and others. prednisolone, which has an anti-inflammatory effect that reduces inflammation and swelling of the tissues of the udder, in the form of a stable suspension on an oil basis. The drug accelerates the regeneration of damaged tissue of the udder and does not have an irritating effect on them.

Claims (1)

A drug for the treatment of mastitis in cows during lactation, containing two antibiotics, one of which belongs to the cephalosporins group and a base, characterized in that cefotaxime sodium salt is used as the antibiotic of the cephalosporins group, neomycin sulfate is the second antibiotic, the Riken DMG emulsifier base and the monoglyceride is distilled, and additionally contains an anti-inflammatory agent - prednisone in the following ratio of components,%:
Cefotaxime sodium salt 5.0-9.0 Neomycin sulfate 0.8-1.2 Prednisone 0.1-0.3 Emulsifier Riken DMG 3 Distilled monoglyceride one Vaseline oil up to 100